LATEST PSYCHEDELICS STOCKS NEWS

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common Stock, Nasdaq Listing, and Full Exercise of Underwriter’s Over-Allotment Option

ENGLEWOOD CLIFFS, NJ, Sept. 30, 2022 -- Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the un... Read More...

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022

VANCOUVER, BC, Sept. 29, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the Cantor Neurology & Psychiatry Conference to be held at The Ritz-Carlton in ... Read More...

Ketamine Wellness Centers (KWC) Expands Insurance Coverage with Medicare for Ketamine Therapy Patients

KWC will serve more patients than any other ketamine therapy provider with addition of Medicare, cements status as nation's largest ketamine clinic network in the U.S.  Medicare coverage will be available for patients in eight cities with more to come GILBERT, Ariz., Sept. 29, 2022 - Ketamine Wellness Centers (KWC), the largest ketamine t... Read More...

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for the Company’s ketamine injection and infusion products ... Read More...

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Optimi Health Corp.Optimi aiming to become the first vertically integrated psychedelics firm to formulate and trial MDMA for healthy subjectsVANCOUVER, British Columbia, Sept. 22, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by Health Canada to produce and... Read More...

Psyence Group Receives Phase IIa Clinical Trial Approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA)

TORONTO, Sept. 19, 2022 -- Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) ("Psyence" or the "Company"), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, is delighted to announce that it has received approval for its Phase IIa clinical trial from the Medicines and Healthcare pr... Read More...

Numinus Now Offers Ketamine-Assisted Therapy in Toronto

Treatment will be offered at the Neurology Centre of Toronto in Forest Hill VANCOUVER, BC, Sept. 19, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) ( OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that its Toronto clinic, the Neurol... Read More...

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

TORONTO, Sept. 16, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s Phase I/II clinical study of oral psiloc... Read More...

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics Ltd.TORONTO, Sept. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has filed an amended protocol to the U.S.... Read More...

Numinus provides update on acquisition integration and announces new client financing options

US clinics acquired from Novamind demonstrating continued growth Physical rebranding of clinics is underway Announcing new client financing options in Canada VANCOUVER, BC, Sept. 13, 2022 - Numinus Wellness Inc. ("Numinus", the "Company") (TSX: NUMI) ( OTCQX: NUMIF) is pleased to provide an update on the integration of the Novamind acqu... Read More...

Lobe Sciences Announces Closing of Private Placement

Vancouver, British Columbia--(Newsfile Corp. - September 8, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announced that it has closed a non-brokered private placement of unit... Read More...

Delic Corp to Present on Strategy and Expansion of Nation’s Largest Ketamine Clinic Network at H.C. Wainwright Annual Global Investment Conference

Matt Stang, executive chairman of Delic, will discuss the company's efforts to grow the clinic footprint, accept a wider selection of insurance options, and its strategic outlook for the remainder of the yearVANCOUVER, BC, Sept. 8, 2022 - Delic Holdings Corp ("Delic") (CSE: DELC) ( OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and t... Read More...

Field Trip Health & Wellness to Present at the H.C. Wainwright 24th Annual Global Investment Conference

TORONTO, Sept. 08, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, today announced it will participate in a virtual fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. A recording of the fires... Read More...

Optimi Health Signs First International Mushroom Supply Agreement with UK-based Avida Global

Optimi Health Corp.EU-GMP, operational, and service excellence to drive world-class sales pipelineFunctional MushroomsFunctional mushrooms grown at Optimi Health facility in Princeton, British Columbia.Lion's ManeLion's Mane mushrooms grown at Optimi Health facility in Princeton, British Columbia.Optimi LifeOptimi Life BundleVANCOUVER, Br... Read More...

Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British Columbia, Sept. 07, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology com... Read More...

Delic Announces Postponement of Meet Delic Conference

Meet Delic will now be held on October 14 and 15, 2023 in Las Vegas Tickets purchased for Meet Delic 2022 will be honored at next year's event VANCOUVER, BC, Sept. 6, 2022 - Delic Holdings Corp ("Delic") (CSE: DELC) ( OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced the postponement of... Read More...

Red Light Holland Announces Live Investor Q&A Session at 2:00 PM (EST) on Thursday, September 8, 2022

Toronto, Ontario--(Newsfile Corp. - September 2, 2022) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America, and a premium brand of psilocybin t... Read More...

Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins

Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results OXNARD, Calif., Sept. 02, 2022 -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary broad platform and wellness technology company, today announced results for the quarter ended June... Read More...

Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible n... Read More...

Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

VANCOUVER, BC, Aug. 31, 2022 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte ... Read More...

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome

VANCOUVER, British Columbia, Aug. 31, 2022 -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that it has dosed the first patient in a Phase I... Read More...

Field Trip Health & Wellness Ltd. Reports Fiscal First Quarter 2023 Financial and Operating Results

Completed corporate reorganization on August 11, 2022 separating the drug development (“Reunion Neuroscience Inc.” or “Reunion”) and healthcare and wellness (“Field Trip Health & Wellness” or “Field Trip”) divisions into two separate public companies (the “Spinout Transaction”).Field Trip received listing approval from the TSX Venture... Read More...

Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors

Optimi Health Corp.Deals position Optimi Life nutraceutical brand for international distributionOptimi LifeOptimi Life BundleOptimi LifeOptimi LifeOptimi LifeOptimi LifeVANCOUVER, British Columbia, Aug. 25, 2022 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a Canadian-based company licensed by H... Read More...

Field Trip Health & Wellness Ltd. Schedules Fiscal First Quarter 2023 Conference Call for Tuesday, August 30, 2022, at 8:30 A.M. ET

TORONTO, Aug. 23, 2022 -- Field Trip Health & Wellness Ltd. (TSXV: FTHW) (the "Company" or “Field Trip”), a global leader in psychedelic therapies, announced today that it plans to release financial results for its fiscal 2023 first quarter for the three-month period ended June 30, 2022, after market close on Monday, August 29, 2022. ... Read More...

Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans

Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other init... Read More...

Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors

DENVER, Aug. 19, 2022 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that it has... Read More...

Pure Extracts Delivers Its Largest Shipments to Launch its Newest Vape Product

VANCOUVER, British Columbia, Aug. 17, 2022 -- Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly-owned subsidiary, Pu... Read More...

Field Trip Health & Wellness Ltd. to Commence Trading on the TSX Venture Exchange on August 17, 2022

TORONTO, Aug. 16, 2022 -- Field Trip Health & Wellness Ltd. (the "Company" of “Field Trip”), a global leader in the development and delivery of psychedelic therapies, is pleased to announce that its common shares (the "Shares") will commence trading on the TSX Venture Exchange (“TSXV”) under the ticker symbol “FTHW” at the opening of ... Read More...

Delic Announces Two Key Executive Appointments

Matt Stang, Co-founder and CEO of Delic, and Kevin Nicholson, COO of Delic, have been elevated to Executive Chairman and Chief Executive Officer, respectively. VANCOUVER, BC, Aug. 16, 2022 - Delic Holdings Corp ("Delic") (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared detail... Read More...